All In Biotech

Drug Trial Radar · NCT07395596

Remimazolam for Bronchoscopy in High-Risk Patients

A Prospective, Randomized Controlled Clinical Study of the Effect of Remimazolam on the Incidence of Hypoxia in High-risk Patients Undergoing Painless Tracheoscopy

Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Feb 9, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shaoxing People's Hospital; Affiliated Hospital of Jiaxing University; The Second Affiliated Hospital of Jiaxing University
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bronchoscopy is currently widely used for the diagnosis and treatment of various respiratory diseases. However, the operation of bronchoscopy is irritating, causes a strong stress response, and shares the airway with the patient, making the patient highly susceptible to respiratory and cardiovascular risks. Among these risks, hypoxia is the most common adverse event.Different drug regimens can be selected for anesthesia under deep sedation. The combination of analgesic agents can help reduce coughing during bronchoscopy. Therefore, we employ a combination of sedative and analgesic drugs for painless bronchoscopy procedures. Among sedatives, propofol is the most commonly used. However, due to its disadvantages, such as respiratory and circulatory depression, we have introduced a novel approach combining remimazolam for sedation. The aim is to investigate whether this new regimen, compared to traditional propofol-based sedation, can reduce the incidence of hypoxia, minimize circulatory depression, and lead to faster postoperative awakening and recovery. Additionally, we hope to observe fewer adverse events, such as perioperative nausea and vomiting, excessive secretions, dizziness, and chills.

Conditions

  • Pulmonary Infection
  • Pulmonary Nodule
  • Phthisis
  • Endotracheal Tumour
  • Lymphadenectasis

Interventions

  • propofol and alfentanilDrug

    General anesthesia with spontaneous breathing maintained is administered using propofol and alfentanil.

  • remimazolam combined with propofol and alfentanilDrug

    General anesthesia with spontaneous breathing maintained is administered using remimazolam combined with propofol and alfentanil.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of hypoxia(75% ≤ SpO2 < 90% for <60 s)Time frame: Periprocedural

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affliated Hospital, Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Shaoxing City First People's Hospital

    Shaoxing, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.